Wealthfront Advisers’s VanEck Biotech ETF BBH Stock Holding History
Bought
Maintained
Sold
Other funds holding BBH
MIM
CCA
BFG
Wealthfront Advisers's BBH Position: Q1 2026 in Review
Wealthfront Advisers increased its VanEck Biotech ETF (BBH) stake by 27% in Q1 2026, buying an estimated $287K and bringing the position to 7,004 shares worth $1.32M. The position accounts for ﹤0.01% of the portfolio, ranked #670.
Wealthfront Advisers first reported a position in BBH in Q3 2021 and has held it in 19 quarters since. 112 funds tracked by Wall St. Rank hold BBH as of Q1 2026.
- Wealthfront Advisers held 7,004 shares of VanEck Biotech ETF worth $1.32M as of Q1 2026.
- Wealthfront Advisers bought 1,491 VanEck Biotech ETF shares in Q1 2026, an estimated $287K.
- VanEck Biotech ETF made up ﹤0.01% of Wealthfront Advisers's portfolio in Q1 2026, its #670 holding.
- Wealthfront Advisers first reported a position in VanEck Biotech ETF in Q3 2021 and has held it in 19 quarters since.
- 112 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q1 2026.
Based on Wealthfront Advisers's 13F filing for Q1 2026, filed 5 May 2026.